Use of chemometrics for development and validation of an RP-HPLC method for simultaneous determination of haloperidol and related compounds

Open access

Use of chemometrics for development and validation of an RP-HPLC method for simultaneous determination of haloperidol and related compounds

A rapid resolution reversed-phase high performance liquid chromatographic (RR RP-HPLC) method has been developed and validated for simultaneous determination of haloperidol and six related compounds. Investigated matrix was a laboratory mixture of a therapeutic active substance haloperidol and its six related compounds in concentration ratio 300:1. Experimental design was used during method optimization (full factorial 23 design) and robustness testing (Central Composite Circumscribed design). Three factors: organic phase variation during gradient elution, flow rate and gradient rise time were independent variables. To estimate the system response during the optimization procedure and robustness testing, resolution (Rs) and a chromatographic response function (CRF) were used. Chromatography was performed with the mobile phase containing phosphate buffer pH 6.5 and acetonitrile as organic modifier. Separation was achieved using gradient elution (organic phase fraction changed linearly from 20 to 72 %) over 7 min. A Zorbax Eclipse XDB C18 Rapid Resolution HT 4.6 mm x 50 mm, 1.8 μm particle size, column was used at 25 °C at a flow rate of 1.5 mL min-1. UV detection was performed at 230 nm. The total time for chromatographic separation was 5.5 min with a total analysis time of 7.0 min. The method was validated for its linearity, precision, modal recovery and robustness.

E. Mutschler, H. Derendorf, M. Schhäfer-Korting, K. Elord and K. S. Estes, in Drug Actions, Basic Principles and Therapeutic Aspects, Medpharm Scientific Publishers, Stuttgart 1995, pp. 116-125.

T. Arinobu, H. Hattori, M. Iwai, A. Ishii, T. Kumazawa, O. Suzuki and H. Seno, Liquid chromatographic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine, J. Chromatogr.B 776 (2002) 107-113; DOI:10.1016/S1570-0232(02)00175-7.

G. Theodoridis, M. A. Lontou, F. Michopoulos, M. Sucha and T. Gondova, Study of multiple solid-phase micro extraction combined off-line with high performance liquid chromatography. Application in the analysis of pharmaceuticals in urine, Anal. Chim. Acta 516 (2004) 197-204; DOI: 10.1016/j.aca.2004.04.012.

S. Ouanes, M. Kallel, H. Trabels, F. Safta and K. Bouzouita, Zero-crossing derivative spectro-photometry for the determination of haloperidol in presence of parabens, J. Pharm. Biomed. Anal. 17 (1998) 361-364; DOI: 10.1016/S0731-7085(97)00174-X.

H. S. El-Desoky and M. M. Ghoneim, Assay of the anti-psychotic drug haloperidol in bulk form, pharmaceutical formulation and biological fluids using square-wave adsorptive stripping voltammetry at a mercury electrode, J. Pharm. Biomed. Anal. 38 (2005) 543-550; DOI: 10.1016/j.jpba.2005.01.017.

P. Cutroneo, M. Beljean, R. Phan Tan Luuc and A.-M. Siouffi, Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography, J. Pharm. Biomed. Anal. 41 (2006) 333-340; DOI: 10.1016/j.jpba.2005.10.050.

R. Driouichl, H. Trabelsi and K. A. Bouzouita, Stability-indicating assay for haloperidol syrup by high-performance liquid chromatography, Chromatographia 53 (2001) 629-634; DOI: 10.1007/ BF02493010.

H. Trabelsi, S. Bouabdallah, K. Bouzouita and F. Safta, Determination and degradation study of haloperidol by high performance liquid chromatography, J. Pharm. Biomed. Anal. 29 (2002) 649-657; DOI: 10.1016/S0731-7085(02)00104-8.

International Conference on Harmonization (ICH): Q3A (R2), Impurities in New Drug Substances, EMEA, London 2006.

M. Franck, Impurity Profiling with the Agilent 1200 Series LC System Part 3: Rapid Condition Scouting for Method Development, Agilent Application Note, Agilent Technologies Inc., Waldbronn, 2006; Publication Number 5989-5619EN.

M. Joseph, High-throughput HPLC with Short Columns and New Sub Two-micron Particles, Agilent Application Note, Agilent Technologies Inc., New York, 2003; Publication Number 5988-9615EN.

T. Lundsted, E. Seifert, L. Abramo, B. Thelin, A. Nystorm, J. Pettersen and R. Bergman, Experimental design and optimization, Chemom. Intell. Lab. Syst. 42 (1998) 3-40; DOI: 10.1016/S0169-7439(98)00065-3.

P. W. Araujo and R. G. Brereton, Experimental design II. Optimization. Trends Anal. Chem. 15 (1996) 63-68; DOI: 10.1016/0165-9936(96)80762-X.

S. N. Deming and S. L. Morgan, Experimental Design: A Chemometric Approach, Elsevier, Amsterdam, 1993.

D. Bylund, A. Bergens and S. P. Jacobsson, Optimization of chromatographic separations by use of a chromatographic response function, empirical modeling and multivariate analysis, Chromatographia 44 (1997) 74-80; DOI: 10.1007/BF02466519.

International Conference on Harmonization (ICH): Q2 (R1), Validation of Analytical Procedures: Text and Methodology, EMEA, London 2005.

H. Fabre, Robustness testing in liquid chromatography and capillary electrophoresis, J. Pharm. Biomed. Anal. 14 (1996) 1125-1132; DOI: 10.1016/s0731-7085(96)01770-0.

G. A. Lewis, D. Mathieu and R. Phan-Tan-Luu, Pharmaceutical Experimental Design, Marcel Decker, New York 1999

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 154 154 17
PDF Downloads 54 54 7